Wednesday, January 30, 2013

Intensive Insulin Therapy in Critically Ill Hospitalized Patients: Making it Safe and Effective


ABSTRACT

David C. Klonoff, M.D., FACP

Intensive insulin therapy (IIT) for hyperglycemia in critically ill patients has become a standard practice. Target levels for glycemia have fluctuated since 2000, as evidence initially indicated that tight glycemic control to so-called normoglycemia (80–110 mg/dl) leads to the lowest morbidity and mortality without hypoglycemic
complications. Subsequent studies have demonstrated minimal clinical benefit combined with greater hypoglycemic morbidity and mortality with tight glycemic control in this population. The consensus glycemic targets were then liberalized to the mid 100s (mg/dl).
Handheld POC blood glucose (BG) monitors have migrated from the outpatient setting to the hospital environment because they save time and money for managing critically ill patients who require IIT. These devices are less accurate than hospital-grade POC blood analyzers or central laboratory analyzers.
Three questions must be answered to understand the role of IIT for defined populations of critically ill patients: (1) How safe is IIT, with various glycemic targets, from the risk of hypoglycemia? (2) How tightly must BG be controlled for this approach to be effective? (3) What role does the accuracy of BG measurements play in affecting the safety of this method? For each state of impaired glucose regulation seen in the hospital, such as hyperglycemia, hypoglycemia, or glucose variability, the benefits, risks, and goals of treatment, including IIT, might differ.
With improved accuracy of BG monitors, IIT might be rendered even more intensive than at present, because patients will be less likely to receive inadvertent overdosages of insulin. Greater doses of insulin, but with dosing based on more accurate glucose levels, might result in less hypoglycemia, less hyperglycemia, and less glycemic variability. (J Diabetes Sci Technol 2011;5(3):755-767)

Full Text: CLICK HERE

Intensive Insulin Therapy for The Treatment of Hyperglycemia in Critically Ill Adults: A Qualitative Systematic Review and Critical Appraisal of the Evidence


ABSTRACT

Rattan Juneja MD; Michael E. Stuart, MD; Sheri A. Strite

Background: Hyperglycemia in intensive care patients is associated with high mortality, but optimal management of this population with insulin therapy is Methods: We utilized the extensive search from a recent published meta-analysis and conducted an updated search using MEDLINE (2008-2009), the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. We assessed bias of trials using a detailed checklist to document the overall quality of the evidence for mortality and hypoglycemia in intensive care populations.
Findings: We included a total of 17 clinical trials totaling 12,345 patients. All included trials were rated as being at medium risk of bias. We identified eight groups of patients in which intensive insulin treatment has been compared to less intensive insulin therapy. Mortality rates varied by patient population with rates of < 16% in predominantly surgical patients with mixed conditions to nearly 75% in neurosurgical patients. Overall, mortality rates ranged from 4% to 74% but the overall level of evidence for mortality was inconclusive. Hypoglycemia rates ranged from 0% to 94% and the overall level of evidence for hypoglycemia was borderline.
Interpretation: The evidence is insufficient for determining the effect of intensive
insulin treatment compared to less intensive treatment in acutely ill hyperglycemic
patients. The evidence does not justify guideline recommendations for specific glycemic target ranges for adults being treated in intensive care units. Further research is needed, but should be carefully planned with attention to trial bias, populations, type of insulin protocols used, adherence, co-interventions, and frequency of blood glucose testing to avoid the heterogeneity and bias present in currently available research.

Full Text: CLICK HERE

Intensive Insulin Therapy and Mortality in Critically Ill Patients


ABSTRACT

Miriam M Treggiari, Veena Karir, N David Yanez, Noel S Weiss, Stephen Daniel and Steven A Deem

Introduction Intensive insulin therapy (IIT) with tight glycemic control may reduce mortality and morbidity in critically ill patients and has been widely adopted in practice throughout the world. However, there is only one randomized controlled trial showing unequivocal benefit to this approach and that study population was dominated by post-cardiac surgery patients. We aimed to determine the association between IIT and mortality in a mixed population of critically ill patients.
Methods We conducted a cohort study comparing three consecutive time periods before and after IIT protocol implementation in a Level 1 trauma center: period I (no
protocol); period II, target glucose 80 to 130 mg/dL; and period III, target glucose 80 to 110 mg/dL. Subjects were 10,456 patients admitted to intensive care units (ICUs) between 1 March 2001 and 28 February 2005. The main study endpoints
were ICU and hospital mortality, Sequential Organ Failure Assessment score, and occurrence of hypoglycemia. Multivariable regression analysis was used to evaluate mortality and organ dysfunction during periods II and III relative to period I.
Results Insulin administration increased over time (9% period I, 25% period II, and 42% period III). Nonetheless, patients in period III had a tendency toward higher adjusted hospital mortality (odds ratio [OR] 1.15, 95% confidence interval [CI] 0.98, 1.35) than patients in period I. Excess hospital mortality in period III was present primarily in patients with an ICU length of stay of 3 days or less (OR 1.47, 95% CI 1.11, 1.93 There was an approximately fourfold increase in the incidence of hypoglycemia from periods I to III.
Conclusion A policy of IIT in a group of ICUs from a single institution was not associated with a decrease in hospital mortality. These results, combined with the findings from several recent randomized trials, suggest that further study is needed
prior to widespread implementation of IIT in critically ill patients.
Critical Care 2008, 12:R29 (doi:10.1186/cc6807)

Full Text: CLICK HERE

Insulin Therapy for Critical Ill Hospitalized Patients


ABSTRACT

Anastassios G. Pittas, MD; Richard D. Siegel, MD; Joseph Lau, MD

Background: Hyperglycemia is common in critically ill hospitalized patients, and it is associated with adverse outcomes, including increased mortality. The objective of
this meta-analysis was to determine the effect of insulin therapy initiated during hospitalization on mortality in adult patients with a critical illness.
Methods: An electronic search in the Englishlanguage articles of MEDLINE and the Cochrane Controlled Clinical Trials Register and a hand search of key journals and relevant review articles were performed. Randomized controlled trials that reported mortality data on critically ill hospitalized adult patients who were treated
with insulin were selected. Data on patient demographics, hospital setting, intervention (formulation and dosage of insulin, delivery method, and duration of therapy), mortality outcomes, adverse events, and methodological quality were extracted.
Results: Thirty-five trials met the inclusion criteria. Combining data from all trials using a random-effects model showed that insulin therapy decreases short-term mortality by 15% (relative risk [RR], 0.85; 95% confidence interval [CI], 0.75-0.97). In subgroup analyses, insulin therapy decreased mortality in the surgical intensive care unit (RR, 0.58; 95% CI, 0.22-0.62), when the aim of therapy was glucose control (RR, 0.71; 95% CI, 0.54-0.93), and in patients with diabetes mellitus (RR, 0.73; 95% CI, 0.58-0.90). A near-significant trend toward decreasing mortality was seen in patients with acute myocardial infarction who did not receive reperfusion therapy (RR, 0.84; 95% CI, 0.71-1.00). No randomized trials of insulin in the medical intensive care unit were identified.
Conclusion: Insulin therapy initiated in the hospital in critically ill patients has a beneficial effect on shortterm mortality in different clinical settings.
(Arch Intern Med. 2004;164:2005-2011)

Full Text: CLICK HERE

Improvement of Glucose Control in The Intensive Care Unit (An Interdisciplinary Collaboration Study)


ABSTRACT

By Ulrike Holzinger, MD, Monika Feldbacher, RN, Adelbert Bachlechner, RN, Reinhard Kitzberger, MD, Valentin Fuhrmann, MD, and Christian Madl, MD

Background Strict glycemic control in critically ill patients is challenging for both physicians and nurses.
Objectives To determine the effect of focused education of intensive care staff followed by implementation of a glucose control protocol.
Methods A prospective observational study in a medical intensive care unit in a university hospital. After intensive education of nurses and physicians, a glucose control protocol with a nurse-managed insulin therapy algorithm was developed and implemented. Every measured blood glucose value and insulin dose per hour and per day were documented in 36 patients before and 44 patients after implementation of
the protocol.
Results Median blood glucose levels decreased after implementation of the protocol (133 vs 110 mg/dL; P < .001). The amounts of time when patients’ blood glucose levels were less than 110 mg/dL and less than 150 mg/dL increased after implementation of the protocol (8% vs 44%; 75% vs 96%; P<.001). The median use of insulin increased after implementation of the protocol (28 vs 35 IU/day; P=.002). Diabetic patients had higher median blood glucose levels than did nondiabetic patients both before (138 vs 131 mg/dL) and after (115 vs 108 mg/dL; P<.001) implementation, although median insulin use also increased (before implementation, 33 vs 26 IU/day; P=.04; after implementation, 46 vs 30 IU/day; P < .001).
Conclusions Use of a collaboratively developed glucose control protocol led to decreased median blood glucose levels and to longer periods of normoglycemia. Despite increased insulin use, glucose control was worse in diabetic patients.
(American Journal of Critical Care. 2008;17:150-158)

Full Text: CLICK HERE

Hypoglycemic Events in Intesive Care Patients: Analysis by Insulin Administration Method and Sample Type


ABSTRACT

By Marta Raurell Torredà, RN, MSN, Emilia Chirveches Pérez, RN, MSN, Maite Domingo Aragón, RN, Rosa Martínez Ribe, RN, Emma Puigoriol Juvanteny, MStat, and Quintí Foguet Boreu, MD, PhD

Background Intensive insulin treatment is associated with an increased risk of hypoglycemia, so strict glycemic monitoring is essential. The best type of sample for identifying hypoglycemia remains under debate.
Objectives To establish the number of hypoglycemic events in intensive care patients relative to insulin administration method and the method used to collect the blood sample.
Methods Retrospective descriptive study lasting 6 months. Hypoglycemia was defined as a blood glucose level less than 80 mg/dL (mild: 50-79 mg/dL, severe: <50 mg/dL), measured with a bedside glucometer and blood from the arterial catheter
or fingerstick, in critically ill patients who require insulin administered subcutaneously (with sliding scales) or via continuous intravenous perfusion (intense infusion protocol with a nurse-managed insulin therapy algorithm).
Results Analysis of the 6636 samples from 144 critically ill patients revealed 188 mildly hypoglycemic samples (2.8%) and 3 severely hypoglycemic samples (0.04%). The prevalence of mild hypoglycemia was greater when insulin was administered
intravenously (3.2%) rather than subcutaneously (2.3%; P = .04). Among patients receiving insulin intravenously, hypoglycemia was found more often in arterial (4.5%) than in capillary (2.8%) blood (P = .01). The prevalence of hypoglycemia in capillary blood samples did not differ significantly between subcutaneous (2.3%) and intravenous (2.8%) insulin therapies (P = .21).
Conclusions With a target blood glucose level of 110 to 140 mg/dL, few hypoglycemic events are detected in critically ill patients, regardless of whether insulin is administered intravenously or subcutaneously. Analysis of solely arterial samples may yield a higher prevalence of hypoglycemia than otherwise.
(American Journal of Critical Care. 2011;20:e115-e121)

Full Text: CLICK HERE

Hyperglycemia related Mortality in Critically Ill Patients Varies with Admission Diagnosis


ABSTRACT

Mercedes Falciglia, MD; Ron W. Freyberg, MS; Peter L. Almenoff, MD; David A. D’Alessio, MD; Marta L. Render, MD

Objectives: Hyperglycemia during critical illness is common and is associated with increased mortality. Intensive insulin therapy has improved outcomes in some, but not all, intervention trials. It is unclear whether the benefits of treatment differ among specific patient populations. The purpose of the study was to determine the association between hyperglycemia and risk–adjusted mortality in critically ill patients and in separate groups stratified by admission diagnosis. A secondary purpose was to determine whether mortality risk from hyperglycemia varies with
intensive care unit type, length of stay, or diagnosed diabetes. Design: Retrospective cohort study.
Setting: 173 U.S. medical, surgical, and cardiac intensive care units.
Patients: 259,040 admissions from October 2002 to September 2005; unadjusted mortality rate, 11.2%.
Interventions: None.
Measurements and Main Results: A two–level logistic regression model determined the relationship between glycemia and mortality. Age, diagnosis, comorbidities, and laboratory variables were used to calculate a predicted mortality rate, which was then
analyzed with mean glucose to determine the association of hyperglycemia with hospital mortality. Hyperglycemia was associated with increased mortality independent of illness severity. Compared with normoglycemic individuals (70–110 mg/dL), adjusted odds of mortality (odds ratio, [95% confidence interval]) for mean glucose 111–145, 146–199, 200–300, and >300 mg/dL was 1.31(1.26 –1.36), 1.82(1.74 –1.90), 2.13(2.03–2.25), and 2.85(2.58–3.14), respectively. Furthermore, the adjusted odds of mortality related to hyperglycemia varied with admission diagnosis, demonstrating a clear association in some patients (acute myocardial infarction, arrhythmia, unstable angina, pulmonary embolism) and little or no association in others. Hyperglycemia was associated with increased mortality independent of intensive care unit type, length of stay, and diabetes.
Conclusions: The association between hyperglycemia and mortality implicates hyperglycemia as a potentially harmful and correctable abnormality in critically ill patients. The finding that hyperglycemia–related risk varied with admission diagnosis suggests differences in the interaction between specific medical conditions and injury from hyperglycemia. The design and interpretation of future trials should consider the primary disease states of patients and the balance of medical conditions in the intensive care unit studied. (Crit Care Med 2009; 37:000–000).

Full Text: CLICK HERE